Plant Bioactives And Engineered Nano-Carriers In Protein Fibrillation

Anglický jazyk

Plant Bioactives And Engineered Nano-Carriers In Protein Fibrillation

Vydavateľstvo: Self Publish
Rok vydania: 2023
Formát: Paperback
Rozmer: 229 x 152 mm
Jazyk: Anglický jazyk
ISBN: 9785448874857

Na objednávku

41.22 €

bežná cena: 45.80 €

O knihe

Protein fibrillation is a common phenomenon in which proteins lose their functional structure and aggregate into insoluble fibrous structures. This can lead to various diseases such as Alzheimer's and Parkinson's. To prevent protein fibrillation, various approaches have been developed, including the use of plant bioactives and engineered nano-carriers. Plant bioactives are compounds derived from plants that have various beneficial properties, including antioxidant and anti-inflammatory activities. These compounds have been found to inhibit protein fibrillation by interacting with the protein molecules and stabilizing their structure. Some examples of plant bioactives that have been shown to inhibit protein fibrillation include curcumin, resveratrol, and epigallocatechin gallate (EGCG). Engineered nano-carriers are small particles that can be designed to deliver drugs or other therapeutic agents to specific locations in the body. These carriers can also be designed to prevent protein fibrillation by interacting with the protein molecules and preventing them from aggregating. Some examples of engineered nano-carriers that have been used to prevent protein fibrillation include liposomes, polymeric nanoparticles, and dendrimers. Combining plant bioactives with engineered nano-carriers can enhance their effectiveness in preventing protein fibrillation. The bioactives can be loaded into the nano-carriers and delivered directly to the site of protein aggregation, where they can interact with the protein molecules and prevent fibrillation. Overall, the use of plant bioactives and engineered nano-carriers in preventing protein fibrillation shows great promise for the development of new therapeutic approaches for diseases related to protein aggregation.